EYPT News and Press, EyePoint Pharmaceuticals Inc. From 11/15/21

EyePoint Pharmaceuticals (NASDAQ:EYPT) announces six-month interim data from the DAVIO Phase 1 clinical trial of EYP-1901, for the treatment of wet age-related macular degeneration (wet AMD). The data were presented at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting. Six-month...

EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD - Interim six-month results show positive safety data, no dose limiting toxicities, no ocular serious adverse events (SAE...

WATERTOWN, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that management will host a confe...

EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2021 Earnings Conference Call November 03, 2021 08:30 A.M. ET Company Participants George O. Elston - CFO & Head, Corporate Development Nancy Lurker - President & CEO Jay Duker - COO Scott Jones - Chief Commercial Officer Conference Call Partic...

EyePoint Pharmaceuticals (NASDAQ:EYPT): Q3 GAAP EPS of -$0.58 misses by $0.18. Revenue of $9.06M (-42.3% Y/Y) misses by $0.82M. Press Release For further details see: EyePoint Pharmaceuticals EPS misses by $0.18, misses on revenue

– Positive 3-month safety data for Phase 1 EYP-1901 DAVIO trial for the potential treatment of wet AMD featured at American Society of Retina Specialists (ASRS) – – Topline data for DAVIO trial to be presented at American Academy of Ophthalmology (AA...

AAWW, ACLS, ACRE, AGIO, AMRN, AMRX, ATH, ATY, AUPH, AUTL, AVA, BCRX, BDC, BDSI, BGCP, BIP, OTCPK:BMWYY, BR, BRSP, BWA, CDW, CIM, CIO, CLH, CLVS, CPRI, CRL, CRTO, CSTE, CTRA, CVE, CVS, CWH, DFIN, DISCA, OTCQX:DLAKF, OTCPK:DNNGY, DNOW, EAT, EMR, ES, ETR, EVRG, EVRI, EXC, EXPI, EYPT, FDP, FUN, F...

EyePoint Pharmaceuticals (NASDAQ:EYPT) is scheduled to announce Q3 earnings results on Wednesday, November 3rd, before market open. The consensus EPS Estimate is -$0.41 and the consensus Revenue Estimate is $9.88M (-37.1% Y/Y). Over the last 3 months, EPS estimates have seen 3 upward revision...

WATERTOWN, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the appointment of Jay S. Du...

WATERTOWN, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call an...